What causes HAE

There are two different subtypes(2) of HAE based on the underlying genetic defect in the control of the blood protein C1-esterase inhibitor:

Type I HAE: This subtype is characterized by decreased levels of functional C1-INH protein. About 80-85% of patients suffer from this form of the disease.

Type II HAE: This type is associated with normal or increased levels of a dysfunctional C1-INH protein resulting in reduced levels of C1-INH activity.

Type III HAE: Recently a type III has been postulated: HAE type III arises independently of a C1-INH deficiency. It is relatively rare and primarily affects women. In some patients a mutation of factor XII was found.(15, 16-18)

Hereditary angioedema of type I and type II is caused by a defect (mutation) in the gene responsible for producing the protein C1 esterase inhibitor (C1-INH). Unlike other hereditary diseases, the healthy gene cannot compensate for the defect in the other gene in patients with HAE. Therefore, a child has a 50% chance of developing HAE if one parent has the gene mutation.(2,14)

Under normal conditions, C1-INH regulates the body’s production of bradykinin, a locally acting hormone that plays an important role in the control of the dilation (widening) and permeability of blood vessels – for example, in response to an injury or infection. If the C1-INH is not functioning properly or if its concentration is decreased, bradykinin is released excessively resulting in local swellings (edema).

Besides the contact system, C1-INH is also involved in the so called complement system which is part of the immune defense. As in the contact system, an external stimulus, for example a foreign body or microbe, triggers a reaction cascade which aims to eliminate the alien.

The cascade starts with the protein C1, whose direct counterpart is C1-INH. C1 is activated as soon as the immune system detects a foreign body, although the process is also self-activating to a lesser extent. Activated C1 activates a series of other factors in the complement system resulting in the elimination of the pathogen.

Infections, injuries, operations or stress(8) may lead to consumption of C1-INH and may thus result in elevation of bradykinin levels with subsequent edema formation. Drugs that lower blood pressure (ACE inhibitors) can also cause edema: by inhibiting the degradation of bradykinin its level is increased.

The role of bradykinin

Bradykinin is a naturally occurring peptide hormone that consists of nine amino acids and is formed locally in tissue. It is involved in the mediation of pain in the event of injury or inflammation. It increases the permeability of the vessels, dilates the blood vessels and causes smooth muscle to contract. In hereditary angioedema, bradykinin is the key mediator for the development of swelling.

It is part of a blood coagulation subsystem known as the contact system, which is regulated by C1-INH. If bradykinin levels are increased, fluids will pass through the vessel walls into the surrounding tissue causing the local swelling of an HAE attack.

After activation of the contact system by an external stimulus like an injury, a complex cascade of different steps follows ending up in the release of bradykinin. Main factors within the contact system are the factor XII and kallikrein.

Finally, after binding to the bradykinin receptor, bradykinin triggers a series of reactions in the tissues(19-23):

• Bradykinin increases the permeability of the vessels (vascular permeability), which allows liquid to pass into the tissues and therefore causes edema.

• Bradykinin widens the blood vessels (vasodilatation) and lowers blood pressure.

• Bradykinin causes the smooth muscle in the tissues to contract, producing cramps and pain.

C1-INH can normally inhibit (stop) the reaction cascade at two points: by preventing self-activation of factor XII and by inhibiting the release of bradykinin from HMW kininogen. In case of C1-INH deficiency release of bradykinin is no longer efficiently controlled. Bradykinin levels increase and edema develops.

News

Tue, 2012-02-14

Pharming And Transmedic Announce Distribution Agreement For Ruconest

Fri, 2012-02-10

Pharming Announces Initiation Of A Pediatric Phase II Clinical Study With Ruconest

Tue, 2012-02-07

ViroPharma Provides Update on Industrial Scale Supplement for Cinryze® (C1 Esterase Inhibitor [Human])

Mon, 2012-02-06

U.S. Senate Declares May 16, 2012 as Hereditary Angioedema Awareness Day

Tue, 2012-01-24

New Data Published On Ruconest's Effect On Blood Clotting Parameters During HAE Attacks

Fri, 2012-01-13

Health Canada Grants Priority Review Status For New Drug Submission (NDS) For Cinryze™ (C1 Inhibitor [human])

Newsletter Teaser ( In News Section on Homepage )

Newsletter

Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.

Sign up for HAEi Newsletter and register at the same time.


Join our Facebook group - and follow HAEi on Twitter

Facebook logo SFacebook logo STwitter logo STwitter logo S

  

Events

Fri, 2012-05-18 08:00 - Sun, 2012-05-20 12:00

2012 HAE Global Conference

Venue:Scandic Hotel Sydhavnen, Copenhagen, Denmark
Language:English

HAE GLOBAL CONFERENCEHAE GLOBAL CONFERENCE

HAEi is delighted to invite patients, care givers, health care professionals and industry representatives to this biannual first true global conference, where this year's theme is "Advocacy and Access".

We have prepared some VERY ATTRACTIVE conference packages for all delegates.

We expect participation from all over the world.

Read more on the 2012 HAE Global Conference website

 

..continue
Wed, 2012-05-16 00:01 - 23:59

2012 HAE Awareness Day

Venue: All over the World!
Language: All languages

HAEDAYHAEDAYPlease have a look at www.haeday.org for more information about this first ever dedicated awareness day for hereditary angioedema (HAE). Find inspiration for national/regional events as well as an overview of planned activities on the hae day website.

..continue
Fri, 2012-03-02 08:00 - Tue, 2012-03-06 17:00

AAAAI 2012 Annual Meeting

Venue: Orange County Convention Center, Orlando, Florida, USA
Language: English

The AAAI Annual Meeting is the world's premier gathering of allergy and immunology experts. Attendees include clinicians, academicians, allied health professionals and others interested in allergic and immunologic disease.

The 2012 meeting will take place from March 2 - 6, in Orlando, Florida. We look forward to seeing you in Orlando. Read more about the conference here

..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


HAEi is a proud supporter of EURORDIS/NORD Rare Disease Day

RDD logoRDD logo


HAEDAYHAEDAYLook out for the first ever HAE Awareness Day on 16 May 2012


www.haeday.org